A registry-based study evaluating overall survival and treatment duration in Swedish patients with metastatic castration-resistant prostate cancer treated with enzalutamide-Reference-Cited by-同舟云学术

A registry-based study evaluating overall survival and treatment duration in Swedish patients with metastatic castration-resistant prostate cancer treated with enzalutamide

Published:2019-09-03 Issue:5 Volume:53 Page:312-318
ISSN:2168-1805
Container-title:Scandinavian Journal of Urology
language:en
Short-container-title:Scandinavian Journal of Urology

Author:

Alghazali Mohammed¹,Löfgren Annica¹,Jørgensen Leif²,Svensson Maja³,Fagerlund Karin³,Bjartell Anders¹

Affiliation:

1. Department of Urology, Skåne University Hospital, Malmö, Sweden;

2. IQVIA Solutions a/s, Copenhagen, Denmark;

3. Astellas Pharma a/s – Nordic Operation, Kastrup, Denmark

Publisher

Informa UK Limited

Subject

Urology,Nephrology

Link

https://www.tandfonline.com/doi/pdf/10.1080/21681805.2019.1657494

Reference18 articles.

1. NORDCAN [Internet]. Copenhagen (Denmark): Association of the Nordic Cancer Registries; c2009. Data from the online tool in the NORDCAN database containing prevalence data [updated 2018 June 28; cited 2019 Jul 10]. Available from: http://www-dep.iarc.fr/nordcan/english/frame.asp.

2. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer

3. Nationwide population-based study on the use of novel antiandrogens in men with prostate cancer in Sweden

4. eMC [Internet]. Surrey (United Kingdom): Datapharm Ltd; c2019. Xtandi 40mg soft capsules; [updated 2018 Oct 30; cited 2019 Jul 10]. Available from: https://www.medicines.org.uk/emc/product/3203/smpc.

5. Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world outcomes for first line next-generation hormonal agents in metastatic prostate cancer: a systematic review;Future Oncology;2023-11

2. Time on treatment with abiraterone and enzalutamide in the Patient-overview Prostate Cancer in The National Prostate Cancer Register of Sweden;Acta Oncologica;2021-09-17

3. Update on a real-world study evaluating overall survival and treatment duration in Swedish patients with metastatic castration-resistant prostate cancer treated with enzalutamide;Scandinavian Journal of Urology;2020-04-14

4. Feasibility and efficacy of sequential systemic therapy for metastatic castration-resistant prostate cancer in a rural health care setting;Scandinavian Journal of Urology;2020-02-24